Top Medical Searches

Gilead challenges GSK with strong HIV drug data

A GlaxoSmithKline logo is seen outside one of its buildings in LondonGilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's product, data presented at a medical meeting in Seattle late on Monday showed. Importantly, there were no cases of resistance emerging to the new medicine in the 98-patient Phase II study and no patients discontinued treatment due to kidney problems, which can be an issue with HIV treatments.

Read More..

Be Sociable, Share!
February 14th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us